Does quercetin lower blood pressure?

Quercetin influences the cardiovascular system through several overlapping mechanisms.

Endothelial function and nitric oxide. The endothelium — the thin cellular lining of blood vessels — regulates vascular tone by releasing nitric oxide (NO), which signals smooth muscle to relax and vessels to dilate. Quercetin activates endothelial nitric oxide synthase (eNOS), increasing NO production and promoting vasodilation. It also inhibits the phosphodiesterase enzymes that break down cyclic GMP, the intracellular messenger that keeps smooth muscle relaxed. The net result is lower peripheral vascular resistance and reduced blood pressure⁴.

ACE inhibition. Angiotensin-converting enzyme (ACE) converts angiotensin I to the vasoconstricting peptide angiotensin II, a central driver of hypertension. Quercetin has mild ACE-inhibitory activity, providing a mechanism similar in direction — though far weaker in magnitude — to pharmaceutical ACE inhibitors⁵.

LDL oxidation and plaque prevention. Atherosclerosis begins when LDL cholesterol is oxidized by reactive oxygen species in the arterial wall, triggering an inflammatory cascade. Quercetin's strong antioxidant activity — particularly its ability to chelate metal ions that catalyze oxidation and to scavenge free radicals — reduces LDL oxidation. In cell and animal studies, quercetin consistently reduces markers of oxidative LDL modification, which is considered an early-stage driver of plaque formation^4,5.

Anti-inflammatory vascular protection. NF-κB is a transcription factor that drives the expression of pro-inflammatory cytokines involved in vascular damage, foam cell formation, and endothelial dysfunction. Quercetin inhibits NF-κB activation, reducing the production of TNF-α, IL-1β, and IL-6 in vascular tissue. This anti-inflammatory action complements its antioxidant effects and may partly explain its blood pressure-lowering properties, since chronic vascular inflammation contributes to arterial stiffness⁴.

Blood Pressure: What the Evidence Shows

The blood pressure data for quercetin is among the most consistent in the flavonoid literature. Clinical effects are modest but real.

A 2016 meta-analysis (Serban et al.) pooled 7 randomized controlled trials with 587 participants and found that quercetin supplementation significantly reduced both systolic blood pressure (WMD −3.04 mmHg, 95% CI −5.75 to −0.33) and diastolic blood pressure (WMD −2.63 mmHg, 95% CI −4.25 to −1.01)¹. Subgroup analysis found effects were larger in trials using doses above 500 mg/day and in participants with metabolic syndrome or pre-existing hypertension. Doses below 500 mg/day showed non-significant trends.

A 2022 meta-analysis (Popiolek-Kalisz and Fornal) expanded the evidence base to 10 trials with 841 participants. Across the mixed population, quercetin significantly lowered systolic blood pressure (MD −2.38 mmHg, 95% CI −3.80 to −0.96); the systolic reduction was also significant in the normotensive subgroup (MD −1.82 mmHg, 95% CI −2.43 to −1.20), and diastolic pressure fell significantly in the (pre)hypertensive subgroup (MD −3.14 mmHg, 95% CI −4.44 to −1.84)².

These numbers — roughly 3 mmHg systolic reduction — may seem small, but population-level analyses suggest that sustained reductions of 2–3 mmHg across the population could reduce stroke incidence by 8% and coronary heart disease by 5%.

Post-Heart Attack Evidence

A double-blind, placebo-controlled RCT published in Phytotherapy Research enrolled 88 patients who had survived a myocardial infarction. Participants received either 500 mg/day quercetin or placebo for 8 weeks³. The quercetin group showed significant increases in total antioxidant capacity (TAC) compared to placebo — a meaningful finding, since oxidative stress in post-MI patients accelerates further cardiovascular damage. Effects on blood pressure and inflammatory markers (IL-6, CRP) were not statistically significant in this trial, possibly because the 8-week window was too short to see those changes in a post-MI population already receiving standard medications.

Dosage and Bioavailability

Typical doses used in cardiovascular trials range from 500–1000 mg/day of quercetin, often divided into two doses. Quercetin's bioavailability from standard supplements is moderate — it absorbs better when taken with food (fat enhances absorption) and when formulated as quercetin phytosome (complexed with phosphatidylcholine) or quercetin dihydrate. Encapsulated forms show higher plasma concentrations than powders in comparative studies.

Natural food sources contain much smaller amounts: a large onion provides roughly 30–50 mg, a cup of capers around 170 mg, an apple about 10–15 mg. Getting 500 mg/day from food alone is not realistic for most diets, which is why supplementation is used in cardiovascular studies.

Quercetin is generally well tolerated. At doses below 1000 mg/day, no significant adverse effects have been reported in clinical trials. At very high doses (>1g/day) for extended periods, there are theoretical concerns about nephrotoxicity based on animal data, though human trials have not demonstrated this risk.

Practical Tips

• Effective dose: 500–1000 mg/day, taken with meals for better absorption
• Timing: Split into two doses if taking 1000 mg/day
• Formulation: Quercetin phytosome or quercetin dihydrate tend to absorb better than plain quercetin aglycone powder
• Food sources to include alongside supplementation: raw onions, capers, apples with skin, dark berries, kale, and dill are the richest dietary sources
• Pairs well with: vitamin C (enhances antioxidant recycling) and bromelain (may improve absorption, though evidence is mixed); combined products are commonly available

See our Quercetin — Inflammation, Allergies, and Longevity page for quercetin's other primary uses: anti-inflammatory effects in rheumatoid arthritis, mast cell stabilization for allergies, and its role as a senolytic agent to clear aging cells.

Blood Pressure — Serban et al. (2016)

Serban MC et al. published a systematic review and meta-analysis in the Journal of the American Heart Association (PMID 27405810) pooling seven randomized controlled trials that enrolled 587 participants across different populations including healthy volunteers, metabolic syndrome patients, and type 2 diabetic subjects¹. Trials ranged from 4 to 10 weeks in duration and used quercetin doses from 150 to 1000 mg/day.

Pooled results: significant reductions in both systolic BP (WMD −3.04 mmHg, 95% CI −5.75 to −0.33; p = 0.028) and diastolic BP (WMD −2.63 mmHg, 95% CI −4.25 to −1.01; p = 0.001). Heterogeneity was high (I² = 85% for SBP), reflecting diverse populations and doses.

Key subgroup findings:

• Doses ≥500 mg/day: significant SBP reduction (WMD −4.45 mmHg); doses <500 mg/day: non-significant
• Patients with metabolic syndrome: more pronounced BP reduction vs. healthy subjects
• No significant association between trial duration and effect size

Limitations: High between-study heterogeneity limits meta-analytic precision. Most trials were small (15–93 participants), and few assessed dietary quercetin intake at baseline. Publication bias assessment via funnel plot was inconclusive given the small number of trials.

Updated Meta-Analysis — Popiolek-Kalisz and Fornal (2022)

Popiolek-Kalisz J and Fornal E updated the evidence base in Current Problems in Cardiology (PMID 35948195) incorporating trials published through 2022, for a total of 10 studies and 841 participants². They specifically examined subgroups by hypertension status, comparing (pre)hypertensive and normotensive adults.

In the mixed population, quercetin significantly decreased systolic BP (MD −2.38 mmHg, 95% CI −3.80 to −0.96; P = 0.01). The systolic reduction was also significant in the normotensive subgroup (MD −1.82 mmHg, 95% CI −2.43 to −1.20; P < 0.0001), and diastolic BP fell significantly in the (pre)hypertensive subgroup (MD −3.14 mmHg, 95% CI −4.44 to −1.84; P < 0.00001).

The authors concluded that quercetin supplementation decreases blood pressure in both normotensive and (pre)hypertensive adults.

Limitations: Moderate to high heterogeneity persists across trials. There remains significant variation in quercetin formulation, dose timing, and co-supplements across trials. The majority of evidence still comes from relatively short-duration trials (≤12 weeks).

Post-MI Antioxidant RCT — Dehghani et al. (2021)

Dehghani F et al. conducted a double-blind, placebo-controlled trial (PMID 33216421) in Phytotherapy Research enrolling 88 post-myocardial infarction patients at Iran University of Medical Sciences, randomized to 500 mg/day quercetin or placebo for 8 weeks³. Primary outcomes included inflammatory markers (CRP, IL-6) and quality of life.

The key finding was a significant increase in total antioxidant capacity (TAC) in the quercetin group versus placebo (p < 0.05). The insecurity dimension of quality-of-life (measured by the MacNew Heart Disease Health-Related Quality of Life questionnaire) also improved significantly in the quercetin group.

IL-6, CRP, and blood pressure did not reach statistical significance. The authors attribute this partly to the anti-inflammatory and antihypertensive medications most post-MI patients were already receiving — a pharmacological ceiling effect that reduces the observable contribution of a dietary supplement.

Limitations: 8-week duration may be insufficient for inflammatory and blood pressure endpoints in medicated post-MI patients. The study was conducted in a single center with an Iranian population; generalizability to other groups requires further research.

Mechanisms Review — Mirsafaei et al. (2020)

Mirsafaei L et al. published a narrative review in Plant Foods and Human Nutrition (PMID 32588290) synthesizing evidence on quercetin's molecular targets in cardiovascular disease, with emphasis on mechanisms relevant to clinical outcomes⁴. The authors — cardiovascular specialists from Iran and Croatia — assessed preclinical and clinical data together.

The review identifies five overlapping cardiovascular mechanisms: (1) antioxidant scavenging of ROS that oxidize LDL cholesterol; (2) eNOS activation leading to increased vascular NO production and vasodilation; (3) ACE inhibition reducing angiotensin II-mediated vasoconstriction; (4) NF-κB inhibition reducing vascular inflammation; and (5) platelet aggregation inhibition that may reduce thrombotic risk. The authors flag the bioavailability problem as the primary barrier to translating strong preclinical results to clinical trials: oral quercetin is extensively metabolized in the gut and liver, and tissue concentrations in humans may be lower than those used in cell and animal experiments.

Cardiovascular Review — Zhang et al. (2023)

Zhang W et al. published a comprehensive review in Frontiers in Cardiovascular Medicine (PMID 38054093) examining quercetin's therapeutic evidence across hypertension, atherosclerosis, heart failure, and arrhythmia⁵. The review, drawing on both animal models and human clinical data, concludes that evidence for blood pressure reduction and endothelial protection is the strongest, supported by multiple meta-analyses, while evidence for effects on advanced atherosclerosis, heart failure, and arrhythmia remains largely preclinical.

The authors highlight quercetin's effect on arterial stiffness — measured by pulse wave velocity in some trials — as a potentially important mechanism beyond simple blood pressure reduction, since arterial stiffness is an independent cardiovascular risk factor. They call for trials using pulse wave velocity and flow-mediated dilation as co-primary endpoints alongside BP.

Overall Evidence Assessment

Blood pressure reduction: Moderate evidence — two meta-analyses demonstrate modest reductions in blood pressure (a few mmHg) at doses ≥500 mg/day, including significant systolic reductions in normotensive adults in the more recent one. Grade: B.

LDL protection and antioxidant capacity: Moderate mechanistic evidence and supportive human data (elevated TAC in clinical trials). Direct clinical evidence for reduced cardiovascular events is lacking. Grade: B−.

Endothelial function: Mechanistically well-supported; emerging clinical evidence from flow-mediated dilation measurements, but insufficient large-scale RCT evidence. Grade: C+ (promising, insufficient clinical data).

Reduction in cardiovascular events: No direct human trial evidence for reduced MI, stroke, or mortality. Effects on surrogate endpoints (BP, TAC) support plausibility. Grade: insufficient evidence to rate.